A phase 1–2 study (NCT03145181 and NCT04557098) involved 165 r/r MM patients after at least three therapy lines (median, five previous therapy lines), including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. This evidence concerns the gene CD38 and Miyoshi myopathy.